These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 10912578)

  • 21. [Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
    Shirasaka T; Aiba K; Araki H; Suzuki M; Terashima M; Mikami Y
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):456-66. PubMed ID: 10097742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
    Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM
    Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacokinetics of S-1].
    Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
    Shirasaka T
    Jpn J Clin Oncol; 2009 Jan; 39(1):2-15. PubMed ID: 19052037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
    Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A 13-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
    Hayashi T; Hasegawa H; Tanaka G; Ohmae S
    J Toxicol Sci; 1996 Nov; 21 Suppl 3():505-26. PubMed ID: 9021659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
    Sugimachi K; Maehara Y; Horikoshi N; Shimada Y; Sakata Y; Mitachi Y; Taguchi T
    Oncology; 1999 Oct; 57(3):202-10. PubMed ID: 10545788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
    Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
    Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats.
    Korenaga D; Honda M; Yasuda M; Inutsuka S; Nozoe T; Tashiro H
    Eur Surg Res; 2002; 34(5):351-6. PubMed ID: 12364819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [An oral repeated dose toxicity study of a new antineoplastic agent S-1 in dogs. I. A 13-week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study].
    Hayashi T; Yamaguchi S; Kito S; Tanaka G; Kurokawa K; Hirota T
    J Toxicol Sci; 1996 Nov; 21 Suppl 3():527-44. PubMed ID: 9021660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
    Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
    Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Theoretical construction of chemotherapeutic tactics for advanced or recurrent gastrointestinal carcinoma].
    Omura K; Kawakami K; Kanehira E
    Gan To Kagaku Ryoho; 2001 Jan; 28(1):63-8. PubMed ID: 11201382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
    Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
    Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
    Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
    Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry.
    Liu K; Zhong D; Zou H; Chen X
    J Pharm Biomed Anal; 2010 Aug; 52(4):550-6. PubMed ID: 20138454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
    Ohuchida A; Kouchi Y; Sato S; Maeda Y
    J Toxicol Sci; 1996 Nov; 21 Suppl 3():675-89. PubMed ID: 9021668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of combination of TS-1 and low-dose cisplatin on sarcoma-180 mouse sarcoma.
    Suzuki Y; Ishibiki Y; Kawai K; Sasaki M; Matsuda M; Watanabe T; Shirasaka T; Kamano T
    Anticancer Drugs; 2003 Jul; 14(6):475-9. PubMed ID: 12853891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Level of 5-fluorodeoxyuridine 5'-monophosphate in cancerous tissue in patients with gastric cancer under preoperative administration of TS-1. A preliminary study.
    Yamamoto S; Kubota K
    J Exp Clin Cancer Res; 2005 Sep; 24(3):457-62. PubMed ID: 16270533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
    Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M
    Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.